Morgan Stanley
CODX

Morgan Stanley’s Co-Diagnostics CODX Stock Holding History

Morgan Stanley’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$164 Buy
88
+15
+21% +$51 ﹤0.01% 7719
2025
Q4 		$371 Sell
73
-120
-62% -$1.31K ﹤0.01% 7560
2025
Q3 		$1.99K Sell
193
-5
-3% -$47 ﹤0.01% 7309
2025
Q2 		$1.67K Sell
198
-1
-0.5% -$9 ﹤0.01% 7259
2025
Q1 		$1.85K Sell
199
-528
-73% -$10.1K ﹤0.01% 7190
2024
Q4 		$16.4K Buy
727
+242
+50% +$7.64K ﹤0.01% 6633
2024
Q3 		$18.2K Sell
485
-189
-28% -$7.25K ﹤0.01% 6536
2024
Q2 		$25.3K Buy
674
+101
+18% +$3.67K ﹤0.01% 6380
2024
Q1 		$19.3K Sell
573
-677
-54% -$24.5K ﹤0.01% 6504
2023
Q4 		$49.9K Buy
1,250
+564
+82% +$19.9K ﹤0.01% 6384
2023
Q3 		$21.8K Sell
686
-268
-28% -$10.1K ﹤0.01% 6454
2023
Q2 		$31.8K Sell
954
-16,421
-95% -$628K ﹤0.01% 6386
2023
Q1 		$771K Buy
17,375
+5,135
+42% +$412K ﹤0.01% 5014
2022
Q4 		$925K Sell
12,240
-415
-3% -$38.9K ﹤0.01% 4913
2022
Q3 		$1.22M Sell
12,655
-4,207
-25% -$588K ﹤0.01% 4767
2022
Q2 		$2.84M Buy
16,862
+16,018
+1,898% +$2.44M ﹤0.01% 4258
2022
Q1 		$156K Sell
844
-1,378
-62% -$285K ﹤0.01% 6050
2021
Q4 		$596K Sell
2,222
-2,355
-51% -$618K ﹤0.01% 5438
2021
Q3 		$1.34M Buy
4,577
+296
+7% +$86.4K ﹤0.01% 4864
2021
Q2 		$1.06M Buy
4,281
+3,217
+302% +$827K ﹤0.01% 5038
2021
Q1 		$304K Sell
1,064
-1,168
-52% -$466K ﹤0.01% 5416
2020
Q4 		$623K Sell
2,232
-3,803
-63% -$1.41M ﹤0.01% 4941
2020
Q3 		$2.46M Buy
6,035
+505
+9% +$259K ﹤0.01% 3463
2020
Q2 		$3.21M Sell
5,530
-6,736
-55% -$3.07M ﹤0.01% 3119
2020
Q1 		$2.8M Buy
+12,266
New +$2.13M ﹤0.01% 3041
2018
Q3 		– Sell
-9
Closed -$1K – 6718
2018
Q2 		$1K Buy
9
+7
+350% +$571 ﹤0.01% 6582
2018
Q1 		$0 Buy
+2
New +$153 ﹤0.01% 6622
2017
Q4 		– Sell
-51
Closed -$10K – 6575
2017
Q3 		$10K Buy
+51
New +$7.79K ﹤0.01% 6168

Other funds holding CODX

PAG
Private Advisory Group Redmond, Washington $1.52B AUM 41.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SAM
Smartleaf Asset Management Boston, Massachusetts $2.77B AUM 22% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
HWA
Heritage Wealth Advisors Richmond, Virginia $2.56B AUM 19.48% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

Morgan Stanley's CODX Position: Q1 2026 in Review

Morgan Stanley increased its Co-Diagnostics (CODX) stake by 21% in Q1 2026, buying an estimated $51 and bringing the position to 88 shares worth $164. The position accounts for ﹤0.01% of the portfolio, ranked #7719.

Morgan Stanley first reported a position in CODX in Q3 2017 and has held it in 28 quarters since. The position peaked at $3.21M in Q2 2020. 14 funds tracked by Wall St. Rank hold CODX as of Q1 2026.

  • Morgan Stanley held 88 shares of Co-Diagnostics worth $164 as of Q1 2026.
  • Morgan Stanley bought 15 Co-Diagnostics shares in Q1 2026, an estimated $51.
  • Co-Diagnostics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #7719 holding.
  • Morgan Stanley first reported a position in Co-Diagnostics in Q3 2017 and has held it in 28 quarters since.
  • Morgan Stanley's Co-Diagnostics position peaked at $3.21M in Q2 2020.
  • 14 funds tracked by Wall St. Rank held Co-Diagnostics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.